Drugs / Imovax® Rabies
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT01877395 | Jun 2013 → May 2014 | rabies | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 2 | NCT01784874 | Feb 2013 → Apr 2014 | rabies | Sanofi Pasteur, a Sanofi Company | Completed | Mixed |
| Comparator or background therapy4 trials | ||||||
| Phase 2 | NCT03145766 Comparator | Apr 2017 → Jan 2018 | rabies | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 2 | NCT01930357 Comparator | Sep 2013 → Aug 2014 | rabies | Sanofi Pasteur, a Sanofi Company | Completed | Met primary |
| Phase 3 | NCT04127786 Comparator | Oct 2019 → Mar 2020 | rabies | Sanofi Pasteur, a Sanofi Company | Completed | Met primary |
| Phase 3 | NCT03965962 Comparator | Jul 2019 → Dec 2020 | — | Sanofi Pasteur, a Sanofi Company | Completed | Met primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Imovax rabies | “This multicenter, observer-blinded Phase II study investigated the safety and immune response of three different doses (antigen content) of PVRV-NG2 versus a licensed human...” PMID 37921410 ↗ Nov 20237“the human diploid cell vaccine (HDCV; Imovax Rabies®)” PMID 38478634 ↗ Jun 2024 “Purified inactivated rabies vaccine - Imovax® Rabies” NCT04127786 ↗ “Imovax® Rabies” NCT01930357 ↗ |
| Known as | HDCV | “the human diploid cell vaccine (HDCV; Imovax Rabies®)” PMID 38478634 ↗ Jun 2024 |
| Modality | Vaccine | “Imovax® Rabies: inactivated rabies vaccine” NCT01784874 ↗ |
| Route | Intramuscular | “Intramuscular” NCT01784874 ↗ |